Annexin Pharmaceuticals AB (publ) (Q910)

Overview

Annexin Pharmaceuticals AB (publ) is a Swedish biotechnology firm that specializes in developing innovative drug candidates aimed at treating a range of cardiovascular diseases. Established in 2014 and headquartered in Stockholm, the company focuses on harnessing the potential of human recombinant proteins to improve vascular health. Its flagship product, ANXV, is designed to protect and repair blood vessels while addressing inflammation associated with various cardiovascular conditions.

Products and Services

• ANXV

  ANXV is a human recombinant protein that plays a crucial role in vascular biology. This product is aimed at safeguarding the integrity of blood vessel structures while also mitigating inflammatory responses that can lead to further cardiovascular issues. Its development is based on scientific principles that explore the importance of Annexin A5 in preventing damage to blood vessels.

• Annexin A5

  Annexin A5 serves as a therapeutic offering intended to protect and repair damaged blood vessels. This product leverages the anti-inflammatory properties of the Annexin A5 protein to effectively counteract the inflammatory processes that can exacerbate cardiovascular conditions. Through the application of this protein, Annexin Pharmaceuticals aims to restore vascular functionality and promote healing within the cardiovascular system.